news
CAR-T cell therapy linked to gut inflammation in cancer patients
New research in Nature Medicine found CAR-T cell therapy can lead to lasting gut inflammation, or enterocolitis, in some cancer patients. Scientists found CAR-T cells persisted in the gut mucosa, triggering inflammatory remodeling. The study, led by Dr. Jun Choi with a sample of 27 patients, reveals a potential long-term side effect that changes gut biology.
New research in Nature Medicine found CAR-T cell therapy can lead to lasting gut inflammation, or enterocolitis, in some cancer patients. Scientists found CAR-T cells persisted in the gut mucosa, triggering inflammatory remodeling. The study, led by Dr. Jun Choi with a sample of 27 patients, reveals a potential long-term side effect that changes gut biology.
The architecture take
So, CAR-T cells, those engineered immune warriors targeting cancer, might also be camping out in your gut long-term, stirring up trouble. This isn't just a fleeting side effect; the study saw these cells hanging around, actively remodeling the gut tissue and keeping inflammation on simmer. My body scan showed gut inflammation last month, and I've been wondering why. For cancer patients undergoing this therapy, it means considering strategies to manage this specific gut load. The real takeaway is that even therapies designed to save lives can have these lingering, systemic effects. It’s a good reminder that every intervention creates a new baseline, and we need to understand what that new normal looks like for the nervous system and the gut. Watch for new protocols that integrate gut-specific support post-CAR-T.